chemmart sitagliptin sitagliptin 100 mg (as phosphate monohydrate) tablet blister pack
arrotex pharmaceuticals pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg) - tablet - excipient ingredients: magnesium stearate; macrogol 8000; calcium hydrogen phosphate; titanium dioxide; hyprolose; croscarmellose sodium; purified talc; iron oxide red; microcrystalline cellulose; hypromellose; iron oxide yellow - sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).
terry white chemists sitagliptin sitagliptin 50 mg (as phosphate monohydrate) tablet blister pack
arrotex pharmaceuticals pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet - excipient ingredients: hyprolose; croscarmellose sodium; calcium hydrogen phosphate; iron oxide yellow; magnesium stearate; titanium dioxide; iron oxide red; macrogol 8000; purified talc; hypromellose; microcrystalline cellulose - sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).
genrx sitagliptin sitagliptin 25 mg (as phosphate monohydrate) tablet blister pack
arrotex pharmaceuticals pty ltd - sitagliptin phosphate monohydrate, quantity: 32.125 mg (equivalent: sitagliptin, qty 25 mg) - tablet - excipient ingredients: purified talc; titanium dioxide; magnesium stearate; microcrystalline cellulose; hypromellose; iron oxide yellow; croscarmellose sodium; hyprolose; macrogol 8000; calcium hydrogen phosphate; iron oxide red - sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).
chemmart sitagliptin sitagliptin 25 mg (as phosphate monohydrate) tablet blister pack
arrotex pharmaceuticals pty ltd - sitagliptin phosphate monohydrate, quantity: 32.125 mg (equivalent: sitagliptin, qty 25 mg) - tablet - excipient ingredients: hypromellose; magnesium stearate; purified talc; microcrystalline cellulose; iron oxide red; macrogol 8000; hyprolose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; iron oxide yellow - sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).
terry white chemists sitagliptin sitagliptin 25 mg (as phosphate monohydrate) tablet blister pack
arrotex pharmaceuticals pty ltd - sitagliptin phosphate monohydrate, quantity: 32.125 mg (equivalent: sitagliptin, qty 25 mg) - tablet - excipient ingredients: titanium dioxide; magnesium stearate; macrogol 8000; hypromellose; calcium hydrogen phosphate; iron oxide red; microcrystalline cellulose; hyprolose; purified talc; croscarmellose sodium; iron oxide yellow - sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).
sitagliptin/metformin sandoz 50/500 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/500 mg film coated tablet blister pack
sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; triethyl citrate; hyprolose; povidone; hypromellose; purified talc; titanium dioxide; microcrystalline cellulose; sodium lauryl sulfate; sodium stearylfumarate; iron oxide red - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.
sitagliptn pcor sitagliptin 50 mg film-coated tablet bottle
pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; povidone; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].
sitagliptin grindeks 100 mg film-coated tablets
as grindeks - sitagliptin hydrochloride monohydrate - film-coated tablet - sitagliptin
sitagliptin grindeks 25 mg film-coated tablets
as grindeks - sitagliptin hydrochloride monohydrate - film-coated tablet - sitagliptin
sitagliptin grindeks 50 mg film-coated tablets
as grindeks - sitagliptin hydrochloride monohydrate - film-coated tablet - sitagliptin